Prisys Biotechnology Co., Ltd.
PrivateLast Round
VC Round
Jun 7, 2021
Total Funding Raised
$28.83M
Company Overview
Prisys Biotechnology Co., Ltd. operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a VC Round in June 2021.
Prisys Biotechnology Co., Ltd. is a biotechnology company that provides preclinical and quasi-clinical evaluation services, including non-human primate disease models and pharmacology research, to support drug development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Imaging, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prisys Biotechnology Co., Ltd. Comparables
Compare Prisys Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kunming Biomed International | 86% | |
| Virscio | 85% | |
| PharmaLegacy | 85% |
For institutional investors. Book with your work email.
Prisys Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jun 7, 2021 | ||||
| Series B | Nov 16, 2020 | ||||
| Pre Seed | May 1, 2017 | ||||
| Angel | Apr 1, 2016 |
For institutional investors. Book with your work email.
Prisys Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hunan Pharmaceutical Development Private Equity Fund Management | Series B |
| Guokejiahe Fund | Series B |
| ZhenFund | Series B |
| Hunan High-tech Venture Capital Group Co., Ltd. | Series B |
| Shenzhen Capital Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 7, 2021
Completed a venture round of funding.
- Nov 16, 2020
$21M round with participation from ZhenFund and others.
For institutional investors. Book with your work email.
Prisys Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prisys Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Prisys Biotechnology Co., Ltd. a public or private company?
Prisys Biotechnology Co., Ltd. is a private company.
What is the current stock price of Prisys Biotechnology Co., Ltd.?
Prisys Biotechnology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Prisys Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prisys Biotechnology Co., Ltd. worth (valuation)?
Valuation information for Prisys Biotechnology Co., Ltd. is not publicly available.
Can I buy Prisys Biotechnology Co., Ltd. stock?
Prisys Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prisys Biotechnology Co., Ltd.'s last funding round?
Prisys Biotechnology Co., Ltd.'s most recent funding round was VC Round on June 7, 2021.
Who are the main investors in Prisys Biotechnology Co., Ltd.?
Key investors in Prisys Biotechnology Co., Ltd. include Hunan Pharmaceutical Development Private Equity Fund Management, Guokejiahe Fund, ZhenFund, Hunan High-tech Venture Capital Group Co., Ltd., Shenzhen Capital Group.
Will Prisys Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Prisys Biotechnology Co., Ltd..
How can I track Prisys Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Prisys Biotechnology Co., Ltd.'s shares on secondary markets.